Bio-Path (NASDAQ:BPTH) Trading Up 15.5%

Bio-Path Holdings Inc (NASDAQ:BPTH)’s share price was up 15.5% on Wednesday . The company traded as high as $8.30 and last traded at $8.25, approximately 459,600 shares traded hands during mid-day trading. A decline of 62% from the average daily volume of 1,203,550 shares. The stock had previously closed at $7.14.

A number of analysts have recently weighed in on BPTH shares. ValuEngine downgraded shares of Bio-Path from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright restated a “buy” rating and issued a $25.00 target price (down from $28.00) on shares of Bio-Path in a report on Monday. Finally, Zacks Investment Research upgraded shares of Bio-Path from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a report on Wednesday.

The business’s fifty day moving average price is $10.17 and its two-hundred day moving average price is $11.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.85 and a current ratio of 13.85. The stock has a market capitalization of $23.79 million, a P/E ratio of -0.57 and a beta of 3.05.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Bio-Path by 10.3% during the 2nd quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock valued at $374,000 after purchasing an additional 2,601 shares during the last quarter. BlackRock Inc. grew its holdings in Bio-Path by 17.5% during the 2nd quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after purchasing an additional 6,978 shares during the last quarter. Finally, Morgan Stanley grew its holdings in Bio-Path by 19,858.0% during the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after purchasing an additional 19,858 shares during the last quarter. Hedge funds and other institutional investors own 6.13% of the company’s stock.

About Bio-Path (NASDAQ:BPTH)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also: What is Cost of Capital?

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.